KAH28851
Colorimetric
Plasma, Serum
Quantitative
15.625-1,000 ng/ml
CV<20%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
AIN457, CAS: 1229022-83-6
Small molecule interleukin (IL) 17A/A antagonists and antibodies blocking both IL17A/A and IL17A/F demonstrate equivalent degrees of efficacy in preclinical models of skin and joint inflammation., PMID:40127522
Preliminary Investigation and Therapeutic Efficacy Determination of a Novel Anti-IL-17A Antibody, Indikizumab., PMID:39319321
Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence., PMID:38499168
Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation., PMID:37222656
Protective effect of Secukinumab on severe sepsis model rats by neutralizing IL-17A to inhibit IKBα/NFκB inflammatory signal pathway., PMID:36253831
Anti-drug antibodies of IL-17 inhibitors for psoriasis: a systematic review., PMID:35972196
Vaccination for SARS-CoV-2 in Patients With Psoriatic Arthritis: Can Therapy Affect the Immunological Response?, PMID:35295608
Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants., PMID:34957149
Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F., PMID:32973785
TNF-α antagonists differentially induce TGF-β1-dependent resuscitation of dormant-like Mycobacterium tuberculosis., PMID:32069329
Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis., PMID:31203228
Are new variants of psoriasis therapy (IL-17 inhibitors) safe?, PMID:31192456
Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years., PMID:31009130
Long-term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study., PMID:30672623
Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis., PMID:29737896
Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders., PMID:28791896
IL-17 for therapy., PMID:28633806
Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review., PMID:28612180
Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study., PMID:28602039
Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis., PMID:27887675
No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents., PMID:27554637
Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis., PMID:27518376
Dry Eye Signs and Symptoms Persist During Systemic Neutralization of IL-1β by Canakinumab or IL-17A by Secukinumab., PMID:26418434
Mining the human autoantibody repertoire: isolation of potent IL17A-neutralizing monoclonal antibodies from a patient with thymoma., PMID:25484038
Pathogenic role of IL-17 in psoriasis and psoriatic arthritis., PMID:25398488
Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapy., PMID:24452484
IL-17 targeted therapies for psoriasis., PMID:23731078
TH17 cell induction and effects of IL-17A and IL-17F blockade in experimental colitis., PMID:23689808
TH17 Cells in Autoimmunity and Immunodeficiency: Protective or Pathogenic?, PMID:22675324
The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases., PMID:22280236
Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis., PMID:20926833
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
